Senores Pharmaceuticals: Unaudited financial results for quarter ended September 30, 2026
Senores Pharmaceuticals (SENORES) filed a disclosure titled "Unaudited financial results for quarter ended September 30, 2026". The company is valued at about ₹5,925 crore.
What happened
Senores Pharmaceuticals (SENORES) filed a disclosure with the exchanges on 29 October 2026 at 01:56 PM titled "Unaudited financial results for quarter ended September 30, 2026".
Company snapshot
Senores Pharmaceuticals is a small-cap company in the Healthcare sector, with a market value of about ₹5,925 crore.
The stock last traded at ₹1,286.6, against a 52-week range of ₹706–₹1,599 (19.5% below the high).
Before this filing the shares had moved −3.3% over the month and −0.6% over three months. Average daily turnover over the last 20 sessions was about ₹29.76 crore.
Promoters held 45.82% at the end of Q1 FY27; 2.81% of promoter shares were pledged. Foreign institutions owned 6.62% and domestic institutions 9.77%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 138 | 19.7 | 4.6 |
| Q2 FY26 | 162 | 32.4 | 6.54 |
| Q3 FY26 | 175 | 31.7 | 7.29 |
| Q4 FY26 | 175 | 36.7 | 7.96 |
| Q1 FY27 | 180 | 30.7 | 6.61 |
What history shows
This is not the company's first results disclosure: BCEIE has 1 earlier filing of this kind on record since May 2026.
Across 300 similar disclosures by other Healthcare companies, shares moved +0.9% on average the next day and +1.8% over five days; 55% of them rose the next day.
Market-wide, 9,836 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 29 October 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Senores Pharmaceuticals Ltd. Estimates – NSE:SENORES
- Senores Pharmaceuticals Reappoints Swapnil Shah as Managing Director
- Senores Pharmaceuticals Q2FY27 Results: Earnings call moved to 4 pm
- Senores Pharma Reappoints Swapnil Shah as Managing Director, Chetan Shah as Whole-Time Director
- Senores Pharmaceuticals (SENORES.NS) Climbs 2.52% to ₹1290.5, Approaches Key Resistance Zone - Supply Zone
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.